Generic placeholder image

Current Medical Imaging

Author(s): Helong Wang, Jing Xu, Yanling Bai, Yewei Wang, Wencheng Shao, Weikang Yun, Lina Feng* and Jianyu Xu*

DOI: 10.2174/1573405620666230906092228

DownloadDownload PDF Flyer Cite As
Predicting the Prognosis of Lung Cancer Patients Treated with Intensitymodulated Radiotherapy based on Radiomic Features

Article ID: e060923220757 Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Aims: This study aimed to develop a method for predicting short-term outcomes of lung cancer patients treated with intensity-modulated radiotherapy (IMRT) using radiomic features detected through computed tomography images.

Methods: A prediction model was developed based on a dataset of radiomic features obtained from 132 patients with lung cancer receiving IMRT. Dimension reduction was performed for the features using the maximum-relevance and minimum-redundancy (mRMR) algorithm, and the least absolute shrinkage and selection operator (LASSO) regression model was utilized to optimize feature selection for the IMRT-sensitivity prediction model. The model was constructed using binary logistic regression analysis and was evaluated using the concordance index (C-index), calibration plots, receiver operating characteristic curve, and decision curve analysis.

Results: Fifty features were selected from 1348 radiomic features using the mRMR method. Of these, three radiomic features were selected by LASSO logistic regression to construct the radiomics nomogram. The C-index of the model was 0.776 (95% confidence interval: 0.689–0.862) and 0.791 (95% confidence interval: 0.607–0.974) in the training and validation cohorts, respectively. Decision curve analysis showed that the radiomics nomogram was clinically useful.

Conclusion: Radiomic features have the potential to be applied to predict the short-term efficacy of IMRT in patients with inoperable lung cancer.

[1]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Huang Y, Feng L, Bao Y, et al. Expressing MLH1 in HCT116 cells increases cellular resistance to radiation by activating the PRKAC. Exp Biol Med (Maywood) 2022; 247(5): 426-32.
[http://dx.doi.org/10.1177/15353702211059829] [PMID: 34787019]
[3]
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553(7689): 446-54.
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]
[4]
Lafata KJ, Hong JC, Geng R, et al. Association of pre-treatment radiomic features with lung cancer recurrence following stereotactic body radiation therapy. Phys Med Biol 2019; 64(2): 025007.
[http://dx.doi.org/10.1088/1361-6560/aaf5a5] [PMID: 30524018]
[5]
Avanzo M, Stancanello J, Pirrone G, Sartor G. Radiomics and deep learning in lung cancer. Strahlenther Onkol 2020; 196(10): 879-87.
[http://dx.doi.org/10.1007/s00066-020-01625-9] [PMID: 32367456]
[6]
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012; 48(4): 441-6.
[http://dx.doi.org/10.1016/j.ejca.2011.11.036] [PMID: 22257792]
[7]
Nardone V, Boldrini L, Grassi R, et al. Radiomics in the setting of neoadjuvant radiotherapy: A new approach for tailored treatment. Cancers (Basel) 2021; 13(14): 3590.
[http://dx.doi.org/10.3390/cancers13143590] [PMID: 34298803]
[8]
Aerts HJWL, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5(1): 4006.
[http://dx.doi.org/10.1038/ncomms5006] [PMID: 24892406]
[9]
Hassani C, Varghese BA, Nieva J, Duddalwar V. Radiomics in pulmonary lesion imaging. AJR Am J Roentgenol 2019; 212(3): 497-504.
[http://dx.doi.org/10.2214/AJR.18.20623] [PMID: 30620678]
[10]
Song J, Shi J, Dong D, et al. A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy. Clin Cancer Res 2018; 24(15): 3583-92.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-2507] [PMID: 29563137]
[11]
Chetan MR, Gleeson FV. Radiomics in predicting treatment response in non-small-cell lung cancer: Current status, challenges and future perspectives. Eur Radiol 2021; 31(2): 1049-58.
[http://dx.doi.org/10.1007/s00330-020-07141-9] [PMID: 32809167]
[12]
Zhu X, Dong D, Chen Z, et al. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer. Eur Radiol 2018; 28(7): 2772-8.
[http://dx.doi.org/10.1007/s00330-017-5221-1] [PMID: 29450713]
[13]
Fornacon-Wood I, Faivre-Finn C, O’Connor JPB, Price GJ. Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype. Lung Cancer 2020; 146: 197-208.
[http://dx.doi.org/10.1016/j.lungcan.2020.05.028] [PMID: 32563015]
[14]
Frix AN, Cousin F, Refaee T, et al. Radiomics in lung diseases imaging: State-of-the-art for clinicians. J Pers Med 2021; 11(7): 602.
[http://dx.doi.org/10.3390/jpm11070602] [PMID: 34202096]
[15]
Ferreira-Junior JR, Koenigkam-Santos M, Magalhães Tenório AP, et al. CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. Int J CARS 2020; 15(1): 163-72.
[http://dx.doi.org/10.1007/s11548-019-02093-y] [PMID: 31722085]
[16]
Kothari G, Korte J, Lehrer EJ, et al. A systematic review and meta-analysis of the prognostic value of radiomics based models in non-small cell lung cancer treated with curative radiotherapy. Radiother Oncol 2021; 155: 188-203.
[http://dx.doi.org/10.1016/j.radonc.2020.10.023] [PMID: 33096167]
[17]
Cong M, Feng H, Ren JL, et al. Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer. Lung Cancer 2020; 139: 73-9.
[http://dx.doi.org/10.1016/j.lungcan.2019.11.003] [PMID: 31743889]
[18]
Yan M, Wang W. Radiomic analysis of CT predicts tumor response in human lung cancer with radiotherapy. J Digit Imaging 2020; 33(6): 1401-3.
[http://dx.doi.org/10.1007/s10278-020-00385-3] [PMID: 33025167]
[19]
Shen C, Liu Z, Guan M, et al. 2D and 3D CT radiomics features prognostic performance comparison in non-small cell lung cancer. Transl Oncol 2017; 10(6): 886-94.
[http://dx.doi.org/10.1016/j.tranon.2017.08.007] [PMID: 28930698]
[20]
Yang L, Yang J, Zhou X, et al. Development of a radiomics nomogram based on the 2D and 3D CT features to predict the survival of non-small cell lung cancer patients. Eur Radiol 2019; 29(5): 2196-206.
[http://dx.doi.org/10.1007/s00330-018-5770-y] [PMID: 30523451]
[21]
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-47.
[http://dx.doi.org/10.1016/j.ejca.2008.10.026] [PMID: 19097774]
[22]
Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007; 26(30): 5512-28.
[http://dx.doi.org/10.1002/sim.3148] [PMID: 18058845]
[23]
Bousabarah K, Blanck O, Temming S, et al. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: Results from two independent institutions. Radiat Oncol 2021; 16(1): 74.
[http://dx.doi.org/10.1186/s13014-021-01805-6] [PMID: 33863358]
[24]
Starkov P, Aguilera TA, Golden DI, et al. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Br J Radiol 2019; 92(1094): 20180228.
[http://dx.doi.org/10.1259/bjr.20180228] [PMID: 30457885]
[25]
Xu Y, Hosny A, Zeleznik R, et al. Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res 2019; 25(11): 3266-75.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2495] [PMID: 31010833]